Exagen Inc. XGN Weighted Average Exercise Price of Vested and Expected to Vest Options
Weighted Average Exercise Price of Vested and Expected to Vest Options at other companies
Other financials
Where this comes from
Reported directly by Exagen Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice.
The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exagen Inc.'s weighted average exercise price of vested and expected to vest options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exagen Inc.'s weighted average exercise price of vested and expected to vest options?
- Exagen Inc. (XGN) reported weighted average exercise price of vested and expected to vest options of $5.91 in Q1 2026.
- How has Exagen Inc.'s weighted average exercise price of vested and expected to vest options changed year-over-year?
- Exagen Inc.'s weighted average exercise price of vested and expected to vest options decreased by 20.4% year-over-year, from $7.42 to $5.91.
- What is the long-term trend for Exagen Inc.'s weighted average exercise price of vested and expected to vest options?
- Over 5 years (2020 to 2025), Exagen Inc.'s weighted average exercise price of vested and expected to vest options has grown at a -10.3% compound annual growth rate (CAGR), from $11.81 to $6.86.
- What does weighted average exercise price of vested and expected to vest options mean?
- The average price at which employees or other stakeholders can purchase company shares for all options that have vested or are expected to vest. This metric helps investors assess the potential cost of equity-based compensation and the alignment between management incentives and shareholder value. It provides a benchmark for the strike price levels relative to the current market price.